Allos Therapeutics (ALTH) implied volatility is elevated ahead of am FDA advisory panel review of the company’s lymphoma drug next Wednesday. Shares are down 60 cents to $7.17 in active trading today after reviewers “raised questions about the findings from Allos Therapeutics for a proposed lymphoma drug” — Reuters (Link to article). Shares are down and trading in the options market is brisk, with some players possibly buying Sep 2.5 – 5 put spreads ahead of the decision. Implied volatility (average) is ripping higher — to 224 from about 181 late Thursday (52-week high and low = 231 and 55).